Back to search results

Gut Microbiome and Cancer Therapy Study

This study is looking at how the bacteria in your gut (gut microbiome) might affect cancer treatment. Researchers want to understand if the gut microbiome influences how well cancer therapies work or if it causes side effects. If you have cancer and are receiving or about to start cancer therapy, or are having a stem cell transplant, you might be able to join. This study involves collecting blood and stool samples and reviewing your medical records. The goal is to find ways to improve cancer treatment and make it more successful. This is an observational study, meaning researchers will watch and collect information without giving new treatments. The study aims to enroll 3000 participants.

Study design
This is an observational study with a planned enrollment of 3000 participants. It is not specified if it's randomized or blinded.
What's involved
Participants will undergo collection of blood and stool samples. Their medical records will also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Associations will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05112614

Role of Gut Microbiome in Cancer Therapy

Recruiting
Not specifiedAges 18–99Observational
Mayo Clinic
~3,000 participants
Updated 2026-03-16 on ClinicalTrials.gov
What's tested:Biospecimen CollectionElectronic Health Record Review

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Gut microbiome associations with cancer diagnoses
Measured over Through study completion, average of 1 year
+1 more outcome measured

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT05112614

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic in Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

  • Mayo Clinic in Arizona

    Scottsdale, Arizonano site contact published

    Active, not recruiting

  • Mayo Clinic in Florida

    Jacksonville, Floridano site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Purna C. Kashyap, MBBS · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-99
Diagnosis of cancer and undergoing cancer therapy or scheduled to start cancer therapy or undergoing stem cell transplant for any hematological condition

Exclusion

Unable to provide informed consent
Vulnerable adults

What this trial measures

  • Gut microbiome associations with cancer diagnosesThrough study completion, average of 1 year

    Will be done using Shogun pipeline for metagenomics data followed by analysis using Quantitative Insights Into Microbial Ecology (QIIME) 2.0.

  • Associations between microbial community abundances and clinical outcomesThrough study completion, average of 1 year

    Will use a linear multivariate regression model specifically developed for microbiome data (MaAsLin, Multivariate microbial Association by Linear models.